To support its international expansion and strengthen technology differentiation, ImmunAdd, Inc. today announced that its proprietary next-generation fully synthetic vaccine adjuvant platform has been formally named ImmSygma™ (ImmunAdd Synthetic GlycoMolecule Adjuvants). The Sygma in the platform name echoes the Greek letter Sigma (Σ), carrying a dual meaning of summation and precision—reflecting both the synergy of […]

ImmunAdd has completed the manufacturing and pharmacology/toxicology studies required for the preclinical trials of its next-generation saponin adjuvant. Offering sustainable supply and lower toxicity, the adjuvant holds significant application value in the vaccine field. The company has been steadily expanding its business development (BD) team and is actively attending major international conferences to engage global […]